Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

532
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
532
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

781
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
781
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

717
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
717

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trauma, Emotional Control, Stress Coping Mechanisms, and Illness Acceptance in Individuals With Orofacial Pain, Headache, and Sleep Bruxism.

Journal of oral rehabilitation·2026
Same author

Differences in concentration of neuron-specific enolase (NSE), neutrophil elastase (NE), and calcium-binding protein S100B in viral diseases: a pilot study focused on normoglycemic COVID-19 patients.

Frontiers in molecular biosciences·2026
Same author

Controversies over the diagnosis of tuberculosis in a patient with rheumatoid arthritis treated with antitumor necrosis factor α agent. Authors' reply.

Polish archives of internal medicine·2026
Same author

Lupus mastitis heralding macrophage activation syndrome: Case report and systematic review of the literature.

Lupus·2026
Same author

Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018-2023.

Infectious diseases and therapy·2026
Same author

Antimicrobial Consumption in The Community Sector in Poland, 2019-2024: Changes and Challenges.

Polish journal of microbiology·2025

Related Experiment Video

Updated: Mar 5, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.6K

Postprandial decrease in LDL-cholesterol in men with metabolic syndrome.

Anna Skoczyńska1, Barbara Turczyn2, Anna Wojakowska2

  • 1Wroclaw Medical University, Department of Internal and Occupational Diseases, and Hypertension, Borowska 213, 50-556 Wrocław, Poland, tel.: 71-7364005, fax: 71-7364009.

Open Medicine (Warsaw, Poland)
|March 30, 2017
PubMed
Summary

Postprandial LDL-cholesterol decreases in men with metabolic syndrome (MetSy) may underestimate cardiovascular risk. Hypolipidemic treatment offered only partial risk reduction, as the apoB/apoA-I ratio remained unchanged.

Keywords:
Postprandial LDL-cholesterolapoB/apoA ratiometabolic syndrome

More Related Videos

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

11.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Mar 5, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.6K
An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

11.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiovascular Disease Research
  • Metabolic Syndrome Studies
  • Lipid Metabolism Analysis

Background:

  • Epidemiological studies often measure blood lipids in non-fasting states, potentially affecting cardiovascular risk assessment.
  • Metabolic syndrome (MetSy) is associated with dyslipidemia and increased cardiovascular risk.
  • Understanding postprandial lipid changes is crucial for accurate risk stratification.

Purpose of the Study:

  • To evaluate changes in low-density lipoprotein cholesterol (LDL-C) after a meal in men with newly diagnosed metabolic syndrome (MetSy).
  • To assess the impact of hypolipidemic treatment on postprandial lipid profiles in men with MetSy.
  • To determine if non-fasting lipid measurements affect cardiovascular risk estimation in this population.

Main Methods:

  • Study included 36 male patients: 12 with MetSy and 24 without.
  • A fat tolerance test was conducted before and after a three-month hypolipidemic treatment.
  • Serum lipids, lipid peroxides (LPO), apolipoproteins (A-I, B), and hsCRP were measured using standard and specialized assays.

Main Results:

  • Postprandial lipemia showed a decrease in LDL-C and apo B in association with increased triglycerides.
  • Men with MetSy exhibited a significantly greater postprandial decrease in LDL-C compared to healthy men.
  • Lipid changes (ΔTG, ΔLDL-C, ΔLPO) were linearly dependent on postprandial non-LDL-cholesterol; apoB/apoA-I ratio remained unchanged post-treatment in MetSy patients.

Conclusions:

  • Postprandial reductions in LDL-C in men with MetSy can lead to an underestimation of their cardiovascular risk.
  • Three months of hypolipidemic therapy provided only partial risk reduction, indicated by the persistent apoB/apoA-I ratio.
  • Non-fasting lipid measurements require careful interpretation in the context of metabolic syndrome.